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Background: Mid-term outcome information in risk stratified patient cohort is needed to 
inform prognosis in individual patients with paragangliomas (PGL), adjuvant therapy choice 
and future research. The objective is to define the outcome relevance of a novel risk 
stratification scheme for PGLs. 
Design: A classification scheme for PGLs was devised and specimen were assessed for invasion 
capacity (infiltrative edges with broad fibrous bands, extra-adrenal extension [recording 
capsular, microscopic periadrenal and gross periadrenal], capsular and peritumoral vascular 
invasion [recording thin- and thick-walled blood vessels]), tumorigenic expansion (expansile 
nodules with diffuse areas, hypercellular homogenous areas, necrosis [recording multifocal 
and confluent subtypes]) and mitogenic activity (MFC/10HPF, presence of atypical mitotic 
figures). Patients were prospectively stratified as low risk or high risk (presence of at least one 
feature of invasive capacity and two features of tumorigenic expansion). Patients underwent 
systematic treatment and follow up for their PGLs in a tertiary referral center. 
Results: The multilevel analysis based on 78 patients identified statistically significant 
differences in clinical and biochemical presentation between low risk and high risk patients for 
gender (p<0.05), noradrenalin (4.6±8.5 vs 11.6±16.9), dopamine (0.6±0.3 vs 1.7±2.4), size of 
lesion (49.8±19.5 vs 89.2±45.8) and malignancy, 0% vs 21.6% (p<0.01), treatment modalities 
for MIBG therapy, 0% vs 40.5% (p<.0001), MVR, 0% vs 23.3% (p<.001) and lymph node 
dissection, 13.5% vs 40.5% (p<0.01) and distant metastases, 0% vs 21.6% (p<0.01). Disease free 
survival was significantly lower in HR patients 0% vs 78.4% (p=0.004). Histological risk 
stratification predicts DFS with AUC of 0.8 (95% CI: 0.69-0.90; p<0.01). 7/37 patients with HR 
had a synchronous diagnosis of malignancy based on other criteria and 4 patients suffered 
local recurrence. 
Conclusions: Stratification as low risk excluded a synchronous diagnosis of malignancy and 
disease recurrence of a follow-up interval of 1-75 months (median 12 months). A high-risk 
status is associated with high risk of malignancy and disease recurrence. 
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